|
Proteome Sciences commercialises its discoveries
through external partnering arrangements by way of out-licensing
and strategic alliances.
Biomarkers
Novel protein biomarkers of disease identified from its internal research
for diagnostic, prognostic or therapeutic applications are out-licensed
to pharmaceutical and diagnostics companies for late stage product
development and commercialisation.
Listed below are a selection of diseases where biomarkers have been
discovered and are available for out-licensing:
Disease |
Application |
Discovery/Validation |
Licensed |
Stroke |
POC |
 |
|
|
Central Labs |
|
|
BSE |
Animals |
|
|
CJD/vCJD |
Blood Screening |
|
Near/mid term |
|
Clinical |
|
Mid term |
Alzheimer’s |
Biomarkers |
|
Near term |
|
Target |
|
Near/mid term |
Organ Rejection |
Acute Coronary |
|
Mid term |
|
Chronic Coronary |
|
Mid term |
|
Renal |
|
Mid term |
Cancer |
Lung |
|
Near/mid term |
|
Breast |
|
Near/mid term |
|
Oesophagus |
|
Near/mid term |
|
Neuroblastoma |
|
Near/mid term |
Metabolic |
Type II Diabetes |
|
Mid/long term |
ProteoSHOP®
The powerful ProteoSHOP® technology platform has been
specifically designed to provide solutions to many of the key problems
and difficulties encountered in protein expression in complex human
samples. Particular emphasis has been concentrated on:
| Membrane and nuclear proteins |
|
| Post translational modifications |
-
Phosphorylation/glycosylation |
| Blood plasma depletion |
|
| Chemical tagging |
-
PST®, qPST™, TMT® to reduce
data complexity |
| Early toxicity/mechanisms of toxicity |
|
| Drug efficiency and mode of action |
|
Proteome Sciences offers strategic alliances and
funded research projects using ProteoSHOP® to major pharmaceutical
and diagnostics companies. These cover existing areas of disease,
new and additional focuses and applications.
To view the ProteoSHOP flyer click here.
Reagents
Proteome Sciences has developed the ‘Sensitizer® Family’ of
reagents with a common feature: these increase the number of peptides
and proteins that can be identified and quantified from complex protein
mixtures. Whilst the ‘Sensitizer®’ feature is common
to all the classes of molecules, the manner in which they achieve their
effect is slightly different in each case, giving each member of the
family a unique application.
These consist of:
Sensitizer® Tags
Sensitizer® |
- |
Increased sensitivity of signal detection
by MALDI-TOF by improved ionization of peptides and subsequent
improved protein identification. CombiSensitizer™ tags
unite peptide signal amplification with relative quantification. |
Protein Sequence Tags®
PST® |
- |
Increased number of protein identification
and relative quantifications by reduction of sample complexity. |
Quantitative Protein Sequence
Tags®
qPST™ |
- |
Isotopically labelled pairs of tags
provide relative protein quantification. |
Tandem Mass Tags®
TMT® |
- |
Isobaric multiplexing ability without
increasing complexity combined with accurate, sensitive protein
identification and quantification. |
Veri-Q |
- |
Reagents to detect levels of impurity
in synthetic oligonucleotides in RNA, RNAi, DNA, microarrays
and QC in synthetic oligonucleotide production. |
Some of these reagents are only provided through ProteoSHOP® strategic
alliances. Licenses can be obtained for the isobaric Tandem Mass
Tags® (TMT®) and the Veri-Q QC reagents/antibodies against
the protecting/de-protecting groups for applications in antisense
therapeutics and oligonucleotide diagnostics.
Site last updated: 7th November 2008
|
